76.93
-1.86 (-2.36%)
| Previous Close | 78.79 |
| Open | 77.95 |
| Volume | 32,494 |
| Avg. Volume (3M) | 1,305,343 |
| Market Cap | 2,658,770,944 |
| Price / Earnings (TTM) | 17.60 |
| Price / Earnings (Forward) | 36.36 |
| Price / Sales | 4.91 |
| Price / Book | 5.51 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.10 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUNDERSON THOMAS J. | - | 75.48 | -9,624 | -726,420 |
| Aggregate Net Quantity | -9,624 | |||
| Aggregate Net Value ($) | -726,420 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 75.48 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GUNDERSON THOMAS J. | Director | 15 Jun 2026 | Sell (-) | 9,624 | 75.48 | 726,420 |
| GUNDERSON THOMAS J. | Director | 15 Jun 2026 | Option execute | 19,285 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |